Key Developments For Akorn, Inc.
Akorn, Inc. (AKRX.O) (Consolidated Issue listed on NASDAQ Global Market)
Akorn, Inc. Launches Acular And Hydralazine Hydrochloride
Akorn, Inc. announced the launch of the generic version of Acular (Ketorolac Tromethamine Ophthalmic). In addition, the Company launched Hydralazine Hydrochloride, an existing generic.
Akorn, Inc. Acquires Capastat Sulfate from Eli Lilly and Company
Akorn, Inc. announced that it has entered into an agreement to acquire from Eli Lilly and Company all rights in the U.S. and Canada to manufacture, market and sell the lyophilized antibiotic Capastat Sulfate (capreomycin for injection, USP). Akorn will own the Capastat NDA and expects to launch the product in the third quarter of this year.
Akorn, Inc. Announces Management Changes
Akorn, Inc. announced the appointment of Raj Rai as Interim Chief Executive Officer while the Board of Directors conducts a search to find a permanent replacement. Mr. Rai replaces Jeffery A. Whitnell, who is leaving the Company to pursue other interests. The Company also announced the appointment of Timothy A. Dick as the its Chief Financial Officer. Mr. Dick will commence his new role on June 15, 2009.
Akorn, Inc. Appoints Jeffrey A. Whitnell As Interim Chief Executive Officer
Akorn, Inc. announced the appointment of Jeffrey A. Whitnell as Interim Chief Executive Officer. As the Company has previously announced, the Special Committee was established to oversee the operations of the Company while the search for a new Chief Executive Officer is underway.
Akorn, Inc. Announces Management Change
Akorn, Inc. announced that its President and Chief Executive Officer, Arthur Przybyl, is leaving the Company and that, pending selection of a new President and Chief Executive Officer, a committee of three board members will oversee operations of the Company and identify Mr. Przybyl`s replacement.
